The U.S. Food and Drug Administration (FDA) placed a hold on Arrowhead Pharmaceuticals‘ Heparc-2004 Phase 2 clinical trial evaluating ARC-520, the company’s investigational medicine for the treatment of chronic hepatitis ... Read more